Population pharmacokinetic analysis of an octreotide depot (CAM2029) in the treatment of acromegaly

MIDD

Endocrinology

Pharmacometrics

Genetic

Clin Pharmacokinet. 2025 Jul;64(7):1079-1092. Online ahead of print.

Glatard A, Friberg-Hietala S, Keutzer L, Hansson A, Johnsson M, Tiberg F.

This publication investigates a novel sustained-release octreotide subcutaneous injection that holds promise for individuals managing the rare chronic disorder acromegaly, caused by an excess of growth hormone.

The research, developed in collaboration with Camurus, focuses on the pharmacokinetic (PK) properties of CAM2029, an innovative treatment designed to offer improved convenience and quality of life for patients.

Current medical treatments for acromegaly, such as octreotide immediate-release (IR) and long-acting repeatable (LAR), present challenges for patients: IR often requires frequent daily dosing, while LAR necessitates professional intramuscular injections, typically on a monthly basis.

CAM2029 is formulated using FluidCrystal® injection depot technology, an approach that enables the gradual and sustained release of octreotide. This allows for administration as infrequently as once every four weeks. Delivered via a patient-friendly autoinjector to provide patients with greater ease in managing their treatment.

The pharmacokinetic (PK) analysis of CAM2029 shows that a 20 mg dose provide a rapid onset of action, and achieves plasma concentrations comparable to those of 0.25 mg octreotide IR. Bioavailability is improved compared to octreotide LAR.

For rare diseases like acromegaly, characterized by smaller patient populations and complex clinical development, advancements in drug formulation and predictable pharmacometrics are not merely advantageous—they are crucial pathways to delivering meaningful new therapeutic options.